We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...

RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sangamo Therapeutics regained development and commercialization rights for its hemophilia A candidate, giroctocogene fitelparvovec, after partner Pfizer conveyed its decision to terminate their ...

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...